Mr. Arianpour joined Ambry Genetics in April of 2009 and currently serves as Vice President of Business Development, responsible for all corporate business development activities, including strategic planning, corporate partnerships and alliances. Mr. Arianpour developed the Genomics division in early 2009 at Ambry Genetics and oversees worldwide sales. Before joining Ambry Genetics, Mr. Arianpour was Manager of Business Development at Cogenics, a division of Clinical Data. Prior to that, he was with Eurogentec North America and DMI Medical in senior sales roles managing and building business opportunities both domestically and internationally. Mr. Arianpour has 12+ years of experience in life science sales, business development and strategic planning. He holds a B.S. in Biological Sciences from the University of California, Irvine and an MBA in Strategic Management from Marshall Goldsmith School of Management at Alliant International University / University of California, San Diego.

Dr. Chao graduated with honors from the University of California, Los Angeles with a B.S. in Microbiology and Molecular Genetics and received her M.D. from University of California, Irvine. As a Howard Hughes Scholar at the National Human Genome Research Institute (NHGRI), Dr. Chao specialized in genomic technologies and cancer genetics. More recently her research has focused on novel methods for interpreting DNA variants. Dr. Chao completed her training in Clinical Molecular Genetics at the Children’s Hospital of Philadelphia (CHOP) and prior to joining Ambry, served as Associate Director of the Genetic Diagnostic Lab at the University of Pennsylvania. 

Dr. Elliott received his undergraduate degree in Biology from Franklin and Marshall College and went on to do his Genetics Ph.D. training at Thomas Jefferson University and Johns Hopkins University School of Medicine. His thesis involved studying the role of CREB-binding protein in germline and stem cell development. Dr. Elliott conducted his postdoctoral training in the cancer stem cell department at the Novartis Institute for Functional Genomics in San Diego, CA., where he studied potential drug targets for chemotherapeutic resistance and identified the first mitochondrial ABC transporter implicated in cancer drug resistance.

Mr. Glade joined Ambry Genetics in 2011 and directs all marketing and branding activities for the company. Prior to Ambry he spent the majority of his career at advertising agencies in New York and San Francisco where he created award-winning campaigns for international brands like AT&T, Microsoft and Intel. His background as a writer, creative director and strategic adviser for consumer and B-to-B brands brings a unique perspective to the lead marketing position. Mr. Glade is a graduate of Brigham Young University, where he studied communication, English and art.

Mr. Keiles began working at Ambry in 2000 where he oversees the client services department. He is also involved in contracting, new product development, pricing, marketing, and research publication. Mr. Keiles obtained his masters degree in genetic counseling from Sarah Lawrence College in 1987. As a genetic counselor at Kaiser Permanente his responsibilities included clinic coordination, program implementation and counseling for all genetic referrals. He was elected the 2009 President of the National Society of Genetic Counselors, where he was responsible for leading the association and serving as the chief spokesperson. Mr. Keiles has more than 20 years of clinical experience and his research publications include molecular diagnostic testing for cystic fibrosis and pancreatitis.